Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Status:
Completed
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, good and/or bad treatment with a new
combination of drugs, cyclophosphamide, topotecan, and bevacizumab has on the patient and
their cancer.
The medications, cyclophosphamide and topotecan, are standard drugs often used together for
the treatment of cancer in children with either Ewing's sarcoma or neuroblastoma.
Bevacizumab is an experimental drug called an antibody that targets a protein important in
the growth of cancer cells called vascular endothelial growth factor (VEGF). VEGF is made by
tumor and other surrounding cells to help make blood vessels needed for the growth and spread
of cancer cells in the body. The way that bevacizumab works is to stop the cancer cells from
making their own blood supply, causing the tumor to stop growing bigger or from spreading. In
adult clinical trials, bevacizumab has shown promising anti-cancer activity in patients with
cancer of the colon/rectum (colorectal) and breast. It has been approved by the Food and Drug
Administration (FDA) for use in patients with colorectal cancer but not in cancers found in
children. Bevacizumab has been tested in early clinical studies in children and has been
shown to be safe.
Other goals of this study will include research tests designed to test the following changes
in the patient or their cancer: to see how the body handles and breaks down bevacizumab
(pharmacokinetics), to look at changes in proteins in the blood that may affect the way the
cancer responds to the combination (angiogenic profile, angiogenesis associated serum
biomarkers), to look at changes in genes that may affect how the cancer responds to treatment
with this combination of medications (metabolic signature), and to monitor the effects of
changes in the way the body grows and develops before and after bevacizumab is given.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Alberta Children's Hospital Children's Mercy Hospital Kansas City Genentech, Inc. M.D. Anderson Cancer Center MD Anderson Cancer Center Orlando Penn State University Phoenix Children's Hospital Center for Cancer & Blood Disorders Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University of Colorado, Denver